Dipyridamole in the treatment of a neonate with persistent pulmonary hypertension

Griffith TM , Edwards DH , Lewis MS , Henderson AH. Evidence that cyclic guanosine monophosphate (cGMP) moderates endothelium-dependent relaxation. Eur J Pharmacol 1985; 112: 195–202.

Ziegler JW , Ivy DD , Fox JJ , Kinsella JP , Clarke WR , Abman SH. Dipyridamole, a cGMP phosphodiesterase inhibitor causes pulmonary vasodilation in the ovine fetus. Am J Physiol 1995; 269: H473–9.

Al-Alaiyan Al Omran , Dyer D. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Intent Car Med 1996; 22: 1093–5.

Ivy DD , Kinsella JP , Ziegler JW , Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998; 115: 875–82.

Kinsella JP , Torielli F , Ziegler JW , Ivy DD , Abman SH. Dipyridamole augmentation of response to nitric oxide. Lancet 1995; 346: 647–8.

Ivy DD , Ziegler JW , Kinsella JP , Wiggins JW , Abman SH. Haemodynamic effects of dypyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Chest 1998; 114(1 suppl): 17S.